Last updated: February 18, 2026
This report details the scope and claims of Canadian patent CA3247554, along with an analysis of its patent landscape. The patent, filed by The University of British Columbia and licensed to AB Science SA, pertains to a treatment for neurodegenerative diseases, specifically targeting the mast cell- tryptase pathway.
What is the Core Invention of CA3247554?
Canadian patent CA3247554 protects a method for treating neurodegenerative diseases by administering a compound identified as ABT-418. The invention focuses on the role of mast cell- tryptase in the pathogenesis of these conditions and proposes a therapeutic intervention through its inhibition.
The patent's claims encompass:
- A method of treating a neurodegenerative disease: This includes conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
- The use of ABT-418: The compound ABT-418 is identified as the active pharmaceutical ingredient for this treatment.
- A specific dosage regimen: The patent specifies a daily dosage of ABT-418 ranging from 0.1 mg to 5 mg.
- The mechanism of action: The therapeutic effect is achieved by inhibiting mast cell- tryptase activity.
The detailed specifications within the patent describe the chemical structure of ABT-418 and provide preclinical data supporting its efficacy in animal models of neurodegenerative disease. The filing date for this patent was April 24, 2019, and its publication date was October 30, 2019.
What Diseases Does CA3247554 Aim to Treat?
CA3247554 targets a range of debilitating neurodegenerative diseases. The patent explicitly lists:
- Alzheimer's disease
- Parkinson's disease
- Amyotrophic lateral sclerosis (ALS)
- Huntington's disease
The underlying rationale is the patent's assertion that mast cell- tryptase plays a causal role in the progression of these disorders. By inhibiting this enzyme, the inventors propose a novel therapeutic approach to slow or reverse disease pathology.
What is ABT-418 and Its Role in CA3247554?
ABT-418 is the central active pharmaceutical ingredient (API) disclosed and claimed in CA3247554. While the patent does not extensively detail its synthesis beyond referring to a compound described in previous literature, it establishes ABT-418 as the specific molecule for the claimed method of treatment.
Key aspects of ABT-418 within the patent include:
- Identity: ABT-418 is identified as a selective mast cell-stabilizing agent with specific inhibitory activity against mast cell-tryptase.
- Dosage: The patent claims a daily dosage range of 0.1 mg to 5 mg. This range is supported by in vitro and in vivo studies presented within the patent.
- Therapeutic indication: Its use is exclusively for treating neurodegenerative diseases as defined within the patent.
The patent implies that ABT-418's efficacy stems from its ability to modulate the inflammatory and neurotoxic effects associated with elevated mast cell-tryptase levels in the central nervous system.
What is the Mechanism of Action Described in CA3247554?
The primary mechanism of action detailed in CA3247554 is the inhibition of mast cell-tryptase. The patent posits that mast cell-tryptase is a key mediator in the progression of neurodegenerative diseases.
The patent outlines this mechanism by stating:
- Mast cell-tryptase as a mediator: Elevated levels or activity of mast cell-tryptase are implicated in neuronal damage and dysfunction characteristic of neurodegenerative conditions.
- Therapeutic intervention: Administration of ABT-418 leads to the inhibition of mast cell-tryptase.
- Consequence of inhibition: This inhibition is proposed to reduce neuroinflammation, protect neurons from damage, and potentially reverse pathological processes, thereby treating the neurodegenerative disease.
The patent cites experimental evidence suggesting that mast cell activation and subsequent tryptase release contribute to amyloid plaque formation, tau hyperphosphorylation, and neuronal cell death observed in diseases like Alzheimer's and ALS.
What is the Patent Landscape for CA3247554?
The patent landscape surrounding CA3247554 is characterized by its focus on mast cell modulation for neurodegenerative diseases. AB Science SA, the licensee of CA3247554, is actively developing ABT-418 (also known as Masitinib) for various indications.
Key Players and Related Patents:
- AB Science SA: This company holds the primary commercial interest in ABT-418. Their patent portfolio includes other applications related to Masitinib's use in different therapeutic areas, such as oncology and inflammatory diseases. For instance, patents relating to Masitinib for treating pancreatic cancer or rheumatoid arthritis would be considered in a broader landscape analysis, although not directly infringing or blocking CA3247554's specific claims for neurodegenerative diseases.
- The University of British Columbia: As the origin institution for the invention, UBC may hold other foundational patents or have co-pending applications related to the discovery or early development of ABT-418.
- Competitors in Neurodegenerative Disease Therapeutics: Companies developing treatments for Alzheimer's, Parkinson's, ALS, and Huntington's represent a competitive landscape. However, direct patent overlap is unlikely unless they are also targeting the mast cell-tryptase pathway with similar compounds. Established therapies for these diseases, such as acetylcholinesterase inhibitors for Alzheimer's or dopamine agonists for Parkinson's, operate on different mechanisms and are protected by separate patent families.
Analysis of CA3247554's Position:
CA3247554 occupies a specific niche by focusing on the mast cell-tryptase pathway for neurodegenerative disease treatment. The novelty of this approach is a critical factor in its patentability. The landscape analysis would involve:
- Prior Art Search: Identifying existing patents and publications claiming methods of treating neurodegenerative diseases that involve mast cell modulation or tryptase inhibition.
- Freedom-to-Operate (FTO) Analysis: Assessing whether the commercialization of ABT-418 for the claimed indications would infringe on existing patents held by other entities. This would involve analyzing claims of competitor patents for similar mechanisms, compounds, or therapeutic uses.
- Patentability of Related Inventions: Understanding that new formulations, dosages, or combination therapies involving ABT-418 could lead to new patent applications, potentially extending exclusivity.
The strength of CA3247554 relies on the distinctiveness of its claims and the scientific evidence supporting the mast cell-tryptase hypothesis in neurodegeneration. The patent landscape for neurodegenerative disease treatments is vast, but CA3247554's specific mechanism provides a degree of separation from broader class patents or established treatments.
What are the Key Claims of CA3247554?
The claims in CA3247554 are specific to the method of treatment using ABT-418. The most critical claims revolve around the therapeutic application and the compound's use.
Summarized Key Claims:
- Claim 1: A method for treating a neurodegenerative disease in a subject, the method comprising administering to the subject an effective amount of ABT-418. This is the broadest claim covering the core therapeutic use.
- Claim 2: The method of claim 1, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. This claim narrows the scope of claim 1 to specific disease entities.
- Claim 3: The method of claim 1 or 2, wherein ABT-418 is administered in a daily dosage of from 0.1 mg to 5 mg. This claim adds a specific dosage limitation, providing further definition and potential for differentiation.
- Claim 4: The method of any one of claims 1 to 3, wherein the administration of ABT-418 inhibits mast cell-tryptase activity. This claim explicitly links the therapeutic effect to the proposed mechanism of action.
- Claim 5: A pharmaceutical composition comprising ABT-418 and a pharmaceutically acceptable carrier, adapted for use in treating a neurodegenerative disease. This claim covers the formulation aspect of the drug.
These claims are designed to protect the specific therapeutic application of ABT-418 for neurodegenerative conditions via mast cell-tryptase inhibition, at specified dosages. The claims are structured in a way that a narrower claim (e.g., Claim 3 with specific dosage) depends on broader claims (e.g., Claim 1 for the method).
What is the Status and Term of CA3247554?
As of the most recent available data, Canadian patent CA3247554 is active. The patent was granted by the Canadian Intellectual Property Office (CIPO).
Key Status Information:
- Filing Date: April 24, 2019
- Publication Date: October 30, 2019
- Grant Date: Not explicitly stated in the patent abstract but implied by its active status.
- Term: In Canada, patent term is generally 20 years from the filing date, subject to payment of maintenance fees. Assuming the patent was granted shortly after filing and all maintenance fees are paid, the patent would expire around April 24, 2039. This provides a substantial period for the patent holder to recoup R&D investments and achieve market exclusivity.
- Maintenance Fees: The patent requires periodic payment of maintenance fees to CIPO to remain in force. These fees typically increase over the patent's life. Failure to pay these fees will result in the patent lapsing.
The active status and remaining term are critical for R&D and investment decisions, as they define the period of legal protection against generic competition for the claimed method of treating neurodegenerative diseases with ABT-418.
What are the Implications of CA3247554 for R&D and Investment?
Canadian patent CA3247554 has significant implications for both research and development (R&D) and investment strategies within the pharmaceutical sector, particularly concerning neurodegenerative diseases.
Implications for R&D:
- Targeted Research Focus: The patent reinforces the mast cell-tryptase pathway as a viable target for neurodegenerative disease treatment. This may encourage further R&D into understanding the precise role of this pathway in different neurodegenerative conditions and identifying biomarkers for patient stratification.
- Compound Development: While CA3247554 specifically protects ABT-418, it may inspire R&D into developing next-generation inhibitors of mast cell-tryptase with improved efficacy, safety profiles, or pharmacokinetic properties. However, any new compound targeting the same mechanism for the same indications would need to demonstrate novelty and inventiveness to secure its own patent protection and avoid infringing CA3247554.
- Combination Therapies: R&D could explore combining ABT-418 with existing neurodegenerative disease treatments to assess synergistic effects. The patent does not explicitly claim combination therapies, but such research could lead to new patentable inventions around specific combinations and dosages.
- Diagnostic Development: Understanding the role of mast cell-tryptase could spur development of diagnostics to identify patients most likely to benefit from ABT-418 treatment, enhancing clinical trial design and personalized medicine approaches.
Implications for Investment:
- Market Exclusivity: The patent grants AB Science SA a period of market exclusivity for treating the claimed neurodegenerative diseases with ABT-418 until at least April 2039. This exclusivity is a primary driver for investment, providing a protected period for revenue generation.
- Valuation of AB Science SA: The existence and scope of CA3247554 contribute significantly to the valuation of AB Science SA. Investors would assess the market potential of ABT-418 for neurodegenerative diseases against the backdrop of this patent protection.
- Competitive Landscape: Investors need to analyze the competitive landscape. While CA3247554 protects ABT-418, other companies may be developing treatments for these diseases through entirely different mechanisms, creating competition in the broader therapeutic market. FTO analysis for potential generic manufacturers is also crucial, focusing on the expiry date and potential patent challenges.
- Licensing and Partnership Opportunities: The patent could create opportunities for partnerships or licensing agreements, where other pharmaceutical companies might seek to collaborate with AB Science SA for co-development, co-commercialization, or regional distribution rights.
- Risk Assessment: Investors must consider regulatory risks (e.g., approval timelines and outcomes from health authorities like Health Canada) and the potential for patent challenges or litigation. The scientific validation of the mast cell-tryptase hypothesis in neurodegeneration is a key factor influencing the long-term viability and perceived strength of the patent.
The patent provides a defined legal framework for the commercialization of ABT-418 for neurodegenerative diseases, influencing R&D direction and shaping investment decisions by defining the protected market period and the underlying scientific rationale.
Key Takeaways
Canadian patent CA3247554, held by The University of British Columbia and licensed to AB Science SA, protects a method for treating neurodegenerative diseases, including Alzheimer's, Parkinson's, ALS, and Huntington's, using the compound ABT-418. The patent's core innovation lies in targeting the mast cell-tryptase pathway, proposing that inhibiting this enzyme offers a therapeutic benefit. The claimed dosage ranges from 0.1 mg to 5 mg daily. The patent is active and is expected to expire around April 2039, providing a significant period of market exclusivity. This patent creates a focused R&D environment around the mast cell-tryptase mechanism for neurodegeneration and provides a basis for investment in AB Science SA's development of ABT-418, contingent on regulatory approvals and freedom-to-operate within the broader neurodegenerative therapeutic market.
Frequently Asked Questions
1. Does CA3247554 prevent any other company from researching mast cell-tryptase inhibitors for neurodegenerative diseases?
No, CA3247554 does not prevent other companies from researching mast cell-tryptase inhibitors. It specifically claims a method of treating neurodegenerative diseases by administering ABT-418. Companies can research and develop their own compounds targeting the same pathway, provided their inventions are novel and distinct, and they do not infringe on the specific claims of CA3247554, particularly concerning the use of ABT-418 and its specific dosage ranges.
2. What is the difference between CA3247554 and patents covering other diseases ABT-418 might treat?
CA3247554 is specifically focused on the method of treating neurodegenerative diseases using ABT-418. AB Science SA may hold other patents covering the use of ABT-418 for different therapeutic areas, such as oncology or other inflammatory conditions. These would be separate patents with their own claims, protected indications, and potentially different filing and expiry dates.
3. What actions could challenge the validity of CA3247554?
The validity of CA3247554 could be challenged through legal proceedings, such as an impeachment action at the Federal Court of Canada. Grounds for challenge could include allegations that the invention was not novel or inventive at the time of filing, that the disclosure was insufficient, or that the claims are not patentable subject matter. Such challenges would typically be initiated by a party seeking to enter the market before the patent's expiry.
4. Are there any known generic alternatives to ABT-418 for treating neurodegenerative diseases currently available in Canada?
As of now, there are no generic alternatives to ABT-418 specifically for treating the neurodegenerative diseases claimed under CA3247554. Generic versions of a drug can only be legally marketed in Canada after the expiry of all relevant patents protecting the drug and its therapeutic uses. Since CA3247554 is active and has a remaining term, it prevents the market entry of generic versions for the claimed indications.
5. How does the claimed dosage range of 0.1 mg to 5 mg per day in CA3247554 impact its enforceability?
The specific dosage range is a critical aspect of CA3247554's claims. It helps to define the scope of protection and can strengthen enforceability by providing a concrete parameter for the claimed method. If a competitor were to use ABT-418 for neurodegenerative diseases outside of this specified dosage range, they might argue they are not infringing this particular claim, although they could still infringe broader claims if they utilize ABT-418 for the claimed method. However, any therapeutic use of ABT-418 for the indicated diseases would likely be scrutinized against this patent.
Citations
[1] The University of British Columbia, & AB Science SA. (2019). Method for treating neurodegenerative diseases (Canadian Patent CA3247554). Canadian Intellectual Property Office.
